These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31931100)

  • 21. Immune dysregulation in sepsis: experiences, lessons and perspectives.
    Cao M; Wang G; Xie J
    Cell Death Discov; 2023 Dec; 9(1):465. PubMed ID: 38114466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Sepsis-Induced Immunosuppression.
    Venet F; Rimmelé T; Monneret G
    Crit Care Clin; 2018 Jan; 34(1):97-106. PubMed ID: 29149944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advancement in the research of mechanism of immune dysfunction in sepsis and the regulatory effects of Xuebijing injection].
    Gao YL; Chai YF; Yao YM
    Zhonghua Shao Shang Za Zhi; 2013 Apr; 29(2):162-5. PubMed ID: 23985206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options.
    Hamers L; Kox M; Pickkers P
    Minerva Anestesiol; 2015 Apr; 81(4):426-39. PubMed ID: 24878876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Balance between Hyperinflammation and Immunosuppression in Sepsis.
    Yadav H; Cartin-Ceba R
    Semin Respir Crit Care Med; 2016 Feb; 37(1):42-50. PubMed ID: 26820273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of sepsis.
    van der Poll T
    Lancet Infect Dis; 2001 Oct; 1(3):165-74. PubMed ID: 11871493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.
    Mei SH; Haitsma JJ; Dos Santos CC; Deng Y; Lai PF; Slutsky AS; Liles WC; Stewart DJ
    Am J Respir Crit Care Med; 2010 Oct; 182(8):1047-57. PubMed ID: 20558630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.
    Jarczak D; Kluge S; Nierhaus A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The beginning of personalized medicine in sepsis: small steps to a bright future.
    Christaki E; Giamarellos-Bourboulis EJ
    Clin Genet; 2014 Jul; 86(1):56-61. PubMed ID: 24579691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier.
    Rivers EP; Jaehne AK; Nguyen HB; Papamatheakis DG; Singer D; Yang JJ; Brown S; Klausner H
    Shock; 2013 Feb; 39(2):127-37. PubMed ID: 23324881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parameters of the Endocannabinoid System as Novel Biomarkers in Sepsis and Septic Shock.
    Lafreniere JD; Lehmann C
    Metabolites; 2017 Nov; 7(4):. PubMed ID: 29104224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advances in immunotherapeutic research of sepsis].
    Dong L; Lyu J; Ding L; Liu Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Feb; 29(2):184-187. PubMed ID: 28625271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pathogenesis of sepsis.
    Stearns-Kurosawa DJ; Osuchowski MF; Valentine C; Kurosawa S; Remick DG
    Annu Rev Pathol; 2011; 6():19-48. PubMed ID: 20887193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovative therapies for sepsis.
    Krishnagopalan S; Dellinger RP
    BioDrugs; 2001; 15(10):645-54. PubMed ID: 11604046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.
    Vincent JL; Sun Q; Dubois MJ
    Clin Infect Dis; 2002 Apr; 34(8):1084-93. PubMed ID: 11914997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic markers of sepsis and septic shock].
    Kübler-Kiełb J; Adamik B
    Postepy Hig Med Dosw; 2000; 54(2):119-32. PubMed ID: 10857376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-Derived Suppressor Cells in Sepsis.
    Schrijver IT; Théroude C; Roger T
    Front Immunol; 2019; 10():327. PubMed ID: 30873175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sepsis: A Review of Advances in Management.
    Rello J; Valenzuela-Sánchez F; Ruiz-Rodriguez M; Moyano S
    Adv Ther; 2017 Nov; 34(11):2393-2411. PubMed ID: 29022217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
    Delano MJ; Ward PA
    J Clin Invest; 2016 Jan; 126(1):23-31. PubMed ID: 26727230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.